Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13844293 | 0.73 | — | — | |
| SCHEMBL2085147 | 0.73 | — | — | |
| SCHEMBL17570611 | 0.68 | TRPV4 (0.38) | TRPV4MAOAMAOB | |
| SCHEMBL27585332 | 0.64 | TSHR (0.45) | — | |
| SCHEMBL5990340 | 0.63 | TSHR (0.34) | — | |
| SCHEMBL101523 | 0.63 | TSHR (0.48) | TRPV4MAOAMAOB | |
| SCHEMBL20562679 | 0.63 | TSHR (0.38) | TRPV4 | |
| SCHEMBL16481702 | 0.63 | TSHR (0.38) | TRPV4 | |
| SCHEMBL13525263 | 0.63 | DHODH (0.40) | TRPV4 | |
| SCHEMBL30283688 | 0.63 | TSHR (0.48) | TRPV4MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260091048-A1 | GIP RECEPTOR AGONIST COMPOUNDS | LILLY CO ELI (US) | 2026-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091048-A1 | GIP RECEPTOR AGONIST COMPOUNDS | GIPR, GLP1R, GPR119 | PTGS2 2150/4885TRPV4 607/4885MAOA 3712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.